NCT01652794View on ClinicalTrials.gov

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

March 31, 2015

Conditions
Leydig Cell TumorOvarian SarcomaOvarian Stromal CancerPseudomyxoma PeritoneiRecurrent Cervical CancerRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal Cavity CancerRecurrent Uterine SarcomaRecurrent Vaginal CancerRecurrent Vulvar Cancer
Interventions
RADIATION

stereotactic body radiation therapy

Undergo SBRT

DRUG

carboplatin

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Optional correlative studies

OTHER

pharmacogenomic studies

Optional correlative studies

Trial Locations (1)

44106

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | Biotech Hunter | Biotech Hunter